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Acute severe bronchospasm is an emergency situation and sometimes these children may
fail to respond to conventional treatment and deteriorate rapidly to respiratory failure requir-
ing mechanical ventilation.We present a case of 2-year-old girl, who presented with severe
bronchospasm resulting in respiratory failure not responding to conventional management
including mechanical ventilation and was found to be H1N1 positive. She was treated with
ketamine infusion, which led to prompt improvement in airway obstruction.
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INTRODUCTION
Wheezing in children is due to narrowing of the intrathoracic
airways (bronchospasm) from illnesses like asthma and bronchi-
olitis, resulting in limitation of expiratory air flow. A recent study
showed that wheezing was present in up to 43.8% of all pandemic
influenza-A (H1N1) cases and was associated with influenza mor-
tality (1). Acute exacerbation of asthma in H1N1 infected cases is
usually diagnosed in presence of wheezing and history of asthma.
Previous studies have shown that asthma was the most common
condition present in both children as well as adults hospitalized
due to H1N1 viral infection, which worsens the respiratory symp-
toms in these cases (2, 3). On the other hand, H1N1 infection
is found to provoke severe exacerbations in asthmatic and atopic
children (3, 4).
Children with acute exacerbations sometimes fail to respond
to standard therapy (i.e., inhaled beta2-agonist and anticholiner-
gics and oral or parenteral corticosteroids) or adjunctive therapies
such as intravenous magnesium, methylxanthines, beta-agonists,
heliox, and non-invasive ventilation requiring invasive ventilation
with associated morbidities (e.g., barotrauma and prolonged hos-
pitalization) (5). Ketamine has been shown to be effective in these
refractory cases both in adults and children (6). Ketamine is a
powerful bronchial relaxant, which relieves bronchospasm and
improves pulmonary compliance in patients with reactive airway
disease and bronchospasm by increasing catecholamine release
and inhibiting catecholamine reuptake processes. We, hereby,
report successful use of ketamine in a child with acute asthma
exacerbation secondary to H1N1infection, who failed to respond
to standard treatment.
CASE DISCUSSION
A 2-year-old girl was admitted with complaints of cough and
high grade fever for 4 days and breathing difficulty for 2 days. She
had history of repeated episodes of respiratory illnesses for which
she received nebulization therapy and responded well. However,
no documentation of medications was available and she was not
on regular inhaled or oral medication. There was no family h/o
atopy or asthma. On admission, she was irritable, febrile (102.6°F),
tachypneic (respiratory rate 56/min) with subcostal and intercostal
retractions and heart rate was 130/min with normal perfusion. Her
oxygen saturation (SpO2) on room air was low (86%). Respira-
tory system examination revealed bilaterally equal and adequate
air entry, bilateral wheezing, and occasional crepitations. Other
systemic examination was unremarkable except for irritability.
Based on history and examination, initial diagnosis of acute
exacerbation of asthma was made and treatment was started
with humidified oxygen and salbutamol nebulization along
with other supportive measures. IV antibiotics (third generation
cephalosporin and aminoglycosides) were started empirically in
view of high grade fever. On complete hemogram, hemoglobin
was 10 g/dl, total leukocyte count – 16000/mm3, and differential
count (P – 54%, L – 35%, M – 6%, E – 4%, B – 1%). However,
bacteriological culture was negative and other basic laboratory
investigations were within normal limits. Chest X-ray revealed
bilateral hyperinflation.
However, despite these measures, she continued to deteriorate
with increasing respiratory distress and SpO2 was varying between
86 and 92%. Therefore, she was shifted to pediatric intensive care
unit (PICU) for further management and was treated sequentially
with ipratropium and budesonide nebulization, IV hydrocortisone
and magnesium sulfate, subcutaneous adrenaline, and IV infusion
of terbutaline and aminophylline over next 10 h. However, her
condition continued to worsen with no improvement in respira-
tory distress. Her arterial blood gas analysis revealed hypoxemia
and respiratory acidosis; therefore, she was intubated and put on
mechanical ventilation.
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Despite several ventilatory changes and supportive measures
over next 12 h, her bronchospasm persisted, SpO2 and ABG para-
meters were worsening. Therefore, we decided to use IV ketamine
as a last measure after taking consent from the parents. Ketamine
was given as initial bolus (0.5 mg/kg) followed by continuous infu-
sion (0.5 mg/kg/h), which increased gradually up to 2 mg/kg/h.
The use of ketamine was not preceded by atropine. Within 4 h,
she started showing response in the form of decrease in wheez-
ing and improvement in peak inspiratory pressure, gas exchange,
and SpO2. The aminophylline, terbutaline, and magnesium infu-
sions were tapered off gradually in 24 h. Her throat swab sent for
H1N1 turned out to be positive so oseltamivir therapy was initi-
ated; however, repeat chest X-ray showed only hyperinflation with
few infiltrates. She showed gradual improvement in clinical condi-
tion and 72 h later, she was extubated to non-invasive ventilation
for next 24 h. Ketamine infusion was continued for 72 h and then
gradually weaned with no side effects of therapy. She was shifted
out of PICU after 5 days and was discharged to home after another
2 days.
DISCUSSION
In the present case, we successfully used ketamine infusion for
refractory bronchospasm in a child with acute asthma exacerba-
tion precipitated by H1N1 infection. Previous studies have sug-
gested that asthma may be a risk factor that worsens respiratory
symptoms during pandemic H1N1 infection and occurrence of
asthma exacerbation might have been increased by H1N1 infec-
tion (1–4). The index case also had history suggestive of asthma
which most probably was precipitated by H1N1 infection. Previ-
ous study showed that children with pandemic H1N1 infection
were more likely to have asthma than children with seasonal
influenza (22 vs. 6%) and usually they present with wheezing and
bronchospasm (4).
Owing to its bronchodilatory effect, ketamine has been success-
fully used to treat patients with severe bronchospasm unresponsive
to conventional (e.g., beta2-agonist, anticholinergics, and corti-
costeroids) as well as adjunctive therapies (e.g., IV magnesium,
methylxanthines, and beta-agonists). Many studies demonstrated
the beneficial use of ketamine for acute exacerbation of asthma
in pediatric patients, both non-ventilated and ventilated (6–8). A
recent review showed a favorable response to ketamine in most of
the studies (5). In non-intubated patients with severe respiratory
distress, ketamine obviated the need for mechanical ventilation
with decrease in wheezing and improvement in SpO2 and blood
gas. Mechanically ventilated patients showed improved peak inspi-
ratory pressures, dynamic compliance of lungs, gas exchange, and
decreased oxygen requirements (6–8).
The suggested mechanisms of airway relaxation include ket-
amine induced inhibition of catecholamine reuptake, increased
catecholamine concentrations, voltage-sensitive Ca++-channel
blockage, and inhibition of postsynaptic nicotinic or muscarinic
receptors. Various authors used ketamine as bolus doses rang-
ing from 0.1 to 2 mg/kg followed by continuous infusion (0.15–
2.5 mg/kg/h) with no major adverse effects (5, 6). Minor adverse
effects reported include dysphoria, hallucinations, increased secre-
tions, and mild perturbations in heart rate and blood pressure in
few patients.
To conclude, present case further supports the use of intra-
venous ketamine as an effective temporizing measure for children
experiencing severe asthma exacerbations refractory to conven-
tional therapy. However, its place in status asthmaticus cannot
be overemphasized where most of the patients respond to con-
ventional drugs and large scale randomized controlled trials are
needed to establish its role as a bronchodilator.
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